



THOMSON MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

PROFIT GUIDANCE ON THE UNAUDITED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2025 AND FINANCIAL YEAR ENDED 30 JUNE 2025

The Board of Directors of Thomson Medical Group Limited (the “**Company**” or “**TMG**”, together with its subsidiaries, the “**Group**”) wishes to announce that following a preliminary review of the unaudited financial results of the Group for the six months ended 30 June 2025 (“**2H2025**”) and the financial year ended 30 June 2025 (“**FY2025**”), the Group is expected to record a loss after tax for 2H2025 and FY2025.

The expected loss in 2H2025 and FY2025 is primarily attributable to higher interest expenses from the FEMVN acquisition; cessation of projects in Singapore; and weaker performance in Malaysia (partly from the termination and discounts of certain insurance contracts).

The Company is in the process of finalising its unaudited financial results for 2H2025 and FY2025. Further details of the Group's financial performance will be disclosed when the Company announces its unaudited financial results for 2H2025 and FY2025 on or before 29 August 2025.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company. Shareholders and investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

By Order of the Board
THOMSON MEDICAL GROUP LIMITED

Dr Heng Jun Li Melvin
Executive Director and Group Chief Executive Officer
8 August 2025